Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors

Expert Rev Vaccines. 2011 Sep;10(9):1307-19. doi: 10.1586/erv.11.88.


Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-level transgene expression from the rHuAd5 vector sustains the CD8(+) T-cell memory population and a nonhematopoietic cell compartment appears to be involved in long-term presentation of adenoviral antigens. Although we are beginning to learn more about the factors that control the maintenance and functionality of memory CD8(+) T cells, we do not yet fully understand what comprises a protective CD8(+) T-cell response. Results from upcoming Phase II clinical trials will be important for determining whether rHuAd5 T-cell vaccines are effective in humans and should help identify correlates of CD8(+) T-cell protection.

Publication types

  • Review

MeSH terms

  • Adenoviruses, Human / genetics
  • Adenoviruses, Human / immunology*
  • Animals
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / virology
  • Clinical Trials, Phase II as Topic
  • Epitopes, T-Lymphocyte / genetics
  • Epitopes, T-Lymphocyte / immunology
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / immunology*
  • HIV / drug effects*
  • HIV / physiology
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • Humans
  • Immunologic Memory*
  • Injections, Intramuscular
  • Macaca
  • Mice
  • Pan troglodytes
  • Vaccination*
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / genetics*
  • Vaccines, Synthetic / immunology


  • Antigens, Viral
  • Epitopes, T-Lymphocyte
  • Vaccines, Synthetic